


**Ce document liste les publications des travaux  
des équipes de recherche du Cancéropôle Grand Ouest,  
sorties de novembre à décembre 2020, classées par réseaux du CGO.**

**Pour accéder plus rapidement aux publications des réseaux qui vous intéressent,  
vous pouvez cliquer directement sur les logos ci-dessous :**



**Et pour les publications inter-réseaux :**



**Réseau « Vectorisation, Imagerie, Radiothérapies »**

[Editorial: Supramolecular Nanomaterials for Engineering, Drug Delivery, and Medical Applications.](#)

Lepeltier E, Levet V, Lee T, Mignet N, Shen J, Fenniri H, Corvis Y.  
Front Chem. 2020 Dec 9;8:626468.

[Microbiota and cancer: In vitro and in vivo models to evaluate nanomedicines.](#)

Ladaycia A, Loretz B, Passirani C, Lehr CM, Lepeltier E.  
Adv Drug Deliv Rev. 2020 Dec 31:S0169-409X(20)30294-5.

[Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm™.](#)

Remoué A, Conan-Charlet V, Deiana L, Tyulyandina A, Marcorelles P, Schick U, Uguen A.  
Hum Pathol. 2020 Nov 24;108:51-59.

[Can alternative PET reconstruction schemes improve the prognostic value of radiomic features in non-small cell lung cancer?](#)

Tankyevych O, Tixier F, Antonorsi N, Filali Razzouki A, Mondon R, Pinto-Leite T, Visvikis D, Hatt M, Cheze Le Rest C.  
Methods. 2020 Nov 14:S1046-2023(20)30251-6.

[Radiomics analysis of 3D dose distributions to predict toxicity of radiotherapy for lung cancer.](#)

Bourbonne V, Da-Ano R, Jaouen V, Lucia F, Dissaux G, Bert J, Pradier O, Visvikis D, Hatt M, Schick U.  
Radiother Oncol. 2020 Nov 6;155:144-150.

[MRI-derived radiomics: methodology and clinical applications in the field of pelvic oncology.](#)

Schick U, Lucia F, Dissaux G, Visvikis D, Badic B, Masson I, Pradier O, Bourbonne V, Hatt M.  
Br J Radiol. 2019 Dec;92(1104):20190105.

[On the production of <sup>52</sup>Gm by deuteron irradiation on natural chromium and its radionuclidic purity.](#)

Bianchi F, Marchi C, Fuad G, Groppi F, Haddad F, Magagnin L, Manenti S.  
Appl Radiat Isot. 2020 Dec;166:109329.

[Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases.](#)

Pichon B, Rousseau C, Blanc-Lapierre A, Delpon G, Ferrer L, Libois V, Le Turnier M, Lenoble C, Bodet-Milin C, Goldenberg DM, Kraeber-Bodere F, Supiot S.  
Biomedicines. 2020 Nov 28;8(12):548

[Head-to-Head Comparison of <sup>18</sup>F-DOPA PET/CT and <sup>68</sup>Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.](#)

Ansquer C, Touchefeu Y, Faivre-Chauvet A, Leux C, Le Bras M, Régenet N, Fleury V, Maucherat B, Senellart H, Guyetant S, Carlier T, Scotet-Cérato E, Rauscher A, Frampas E, Kraeber-Bodéré F.  
Clin Nucl Med. 2020 Dec 7.

[Management of image guidance doses delivered during radiotherapy\]](#)

Delpon G, Lazaro D, de Crevoisier R.  
Cancer Radiother. 2020 Dec 31:S1278-3218(20)30324-3.

[Innovation in radiotherapy in 2021.](#)

Masson I, Dutreix M, Supiot S.  
Bull Cancer. 2020 Dec 7:S0007-4551(20)30438-0.

[Rectal and Urethro-Vesical Subregions for Toxicity Prediction After Prostate Cancer Radiation Therapy: Validation of Voxel-Based Models in an Independent Population.](#)

Mylona E, Ebert M, Kennedy A, Joseph D, Denham J, Steigler A, Supiot S, Acosta O, de Crevoisier R.  
Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1189-1195.

[Stereotactic radiotherapy in urologic cancers: Reports from the 3rd international meeting of the Groupe Francophone de Radiothérapie Urologique \(GFRU\).](#)

Perennec T, Supiot S.  
Bull Cancer. 2020 Dec 24:S0007-4551(20)30492-6.

[Local-Mean Preserving Post-Processing Step for Non-Negativity Enforcement in PET Imaging: Application to 90Y-PET.](#)

Millardet M, Moussaoui S, Mateus D, Idier J, Carlier T.  
IEEE Trans Med Imaging. 2020 Nov;39(11):3725-3736.

[Characterization of Affitin proteolytic digestion in biorelevant media and improvement of their stabilities via protein engineering.](#)

Loussouarn A, Béhar G, Pecorari F, Croyal M, Renodon-Cornière A.  
Sci Rep. 2020 Nov 12;10(1):19703

[Comparaison entre des biopsies ciblées sur l'IRM et le TEP-Choline et des biopsies transpérinéales de saturation pour la détection et la topographie d'une récurrence intra prostatique après une irradiation première d'un cancer de la prostate.](#)

Biscans C, Vallée M, Chalhoub K, Guérif S  
Prog Urol. 2020 Nov;30(13):778.

[The importance of feature aggregation in radiomics: a head and neck cancer study.](#)

Fontaine P, Acosta O, Castelli J, De Crevoisier R, Müller H, Depeursinge A.  
Sci Rep. 2020 Nov 12;10(1):19679.



**Réseau « Cancers des Tissus Hormono-dépendants »**

[Impact de la densité du PSA et de l'IRM multiparamétrique dans l'indication à une surveillance active d'un adénocarcinome prostatique à faible risque.](#)

Saout K, Zambon A, N'Guyen T, Lucas C, Payrard-Starck C, Marolleau J, Segalen T, Tissot V, Doucet L, Deruelle C, Joulin V, Fourcade A, Fournier G, Valeri A  
Prog Urol. 2020 Nov;30(13):835.

[Prédiction de récurrence biologique et de l'envahissement ganglionnaire dans le cancer de prostate : comparaison de la performance des principaux scores prédictifs dans deux populations françaises ethnogéographiques différentes.](#)

Kaulanjan K, Buisset J, Lecoent Q, Perrot E, Carton M, Multigner L, Mathieu R, Villers A, Blanchet P, Bureau L.  
Prog Urol. 2020 Nov;30(13):775-776.

[Syndrome métabolique et cancer de la prostate dans une population d'ascendance afro-caribéenne.](#)

Brureau L, Lefebvre F, Blanchet P, Multigner L, Blanchet A.  
Prog Urol. 2020 Nov;30(13):694-695.

[A cohort study of banana plantation workers in the French West Indies: first mortality analysis \(2000-2015\).](#)

Luce D, Dugas J, Vaidie A, Michineau L, El-Yamani M, Multigner L.  
Environ Sci Pollut Res Int. 2020 Nov;27(33):41014-41022.

[Amélioration de la classification du risque intermédiaire du cancer de la prostate avec les données IRM et anatomopathologiques standards.](#)

Thenault R, Gasmi A, Kaulanjan K, Goujon A, Courboin E, Manunta A, Verhoest G, Vincendeau S, Bensalah K, Khene Z, Peyronnet B, Mathieu R.  
Prog Urol. 2020 Nov;30(13):776.

[Évaluation de l'intérêt de la radiomique dans la prédiction du stade et du grade du cancer de la prostate localisé.](#)

Thenault R, Kaulanjan K, Gasmi A, Goujon A, Courboin E, Manunta A, Mermier M, Peyronnet B, Vincendeau S, Verhoest G, Bensalah K, Khene Z, Mathieu R.  
Prog Urol. 2020 Nov;30(13):771-772.

[Contemporary role of palliative cystoprostatectomy or pelvic exenteration in advanced symptomatic prostate cancer.](#)

Surcel C, Mirvald C, Tsaur I, Borgmann H, Heidegger I, Labanaris AP, Sinescu I, Tilki D, Ploussard G, Briganti A, Montorsi F, Mathieu R, Valerio M, Jinga V, Badescu D, Radavoi D, van den Bergh RCN, Gandaglia G, Kretschmer A; as part of the EAU-YAU PCa Working Party.  
World J Urol. 2020 Nov 1.

[French ccAFU guidelines - update 2020-2022: prostate cancer.](#)

Rozet F, Mongiat-Artus P, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, Fromont-Hankard G, Mathieu R, Ploussard G, Renard-Penna R, Brenot-Rossi I, Bruyere F, Cochet A, Crehange G, Cussenot O, Lebreton T, Rebillard X, Soulié M, Brureau L, Méjean A.  
Prog Urol. 2020 Nov;30(12S):S136-S251.

[Plastie yv robotique et lambeau péritonéal pour sténose d'anastomose vésico-urétrale après prostatectomie radicale et radiothérapie.](#)

Freton L, Alimi Q, Zhao L, Haudebert C, Bourre T, Mermier M, Laine-Caroff P, Hascoet J, Mathieu R, Manunta A, Bensalah K, Peyronnet B.  
Prog Urol. 2020 Nov;30(13):847.

[A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?](#)

Heidegger I, Necchi A, Pircher A, Tsaur I, Marra G, Kasivisvanathan V, Kretschmer A, Mathieu R, Ceci F, van den Bergh RCN, Thibault C, Tilki D, Valerio M, Surcel C, Gandaglia G; EAU-YAU Prostate Cancer Working Party.  
Eur Urol Oncol. 2020 Nov 23:S2588-9311(20)30175-9.

[Management of hormone deprivation therapies in prostate cancer: Role of the nurse.](#)

Kaulanjan K, Thenault R, Leroy V, Khene Z, Mathieu R.  
Prog Urol. 2020 Nov;30(15):958-963.

[Low Levels of Omega-3 Long-Chain Polyunsaturated Fatty Acids Are Associated with Bone Metastasis Formation in Premenopausal Women with Breast Cancer: A Retrospective Study.](#)

Goupille C, Frank PG, Arbion F, Jourdan ML, Guimaraes C, Pinault M, Body G, Chevalier S, Bougnoux P, Ouldamer L.

Nutrients. 2020 Dec 15;12(12):3832.

[Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.](#)

Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Du FL, Dupré PF, Bachelot T, Gabelle P, Chauvet MP, Coeffic D, Barbe C, Prevost JB, Paintaud G, Thibault G, Ferhat A, Dupin J, Berriolo-Riedinger A, Arnould L.

EClinicalMedicine. 2020 Nov 4;28:100566.

[Development of an absolute assignment predictor for triple-negative breast cancer subtyping using machine learning approaches.](#)

Ben Azzouz F, Michel B, Lasla H, Gouraud W, François AF, Girka F, Lecointre T, Guérin-Charbonnel C, Juin PP, Campone M, Jézéquel P.

Comput Biol Med. 2020 Dec 9;129:104171.

[Environmental chemicals, breast cancer progression and drug resistance.](#)

Koual M, Tomkiewicz C, Cano-Sancho G, Antignac JP, Bats AS, Coumoul X.

Environ Health. 2020 Nov 17;19(1):117.

[In vivo comparison of the proangiogenic properties of chlordecone and three of its dechlorinated derivatives formed by in situ chemical reduction.](#)

Alabed Alibrahim E, Legeay S, Billat PA, Bichon E, Guiffard I, Antignac JP, Legras P, Roux J, Bristeau S, Clere N, Faure S, Mouvet C.

Environ Sci Pollut Res Int. 2020 Nov;27(33):40953-40962.

[Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer \(monarchE\).](#)

Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P; monarchE Committee Members and Investigators.

J Clin Oncol. 2020 Dec 1;38(34):3987-3998.

[A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.](#)

Bertho M, Patsouris A, Augereau P, Robert M, Frenel JS, Blonz C, Campone M.

Expert Opin Drug Metab Toxicol. 2020 Dec 8:1-14.

[Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2- Advanced Breast Cancer.](#)

Bardia A, Modi S, Oliveira M, Cortes J, Campone M, Ma B, Dirix L, Weise A, Hewes B, Diaz-Padilla I, Han Y, Deshpande P, Samant TS, Lorenc KR, He W, Su F, Chavez-MacGregor M.

Clin Cancer Res. 2020 Dec 15;26(24):6417-6428.



**Réseau « Immunothérapies »**

[Macrophages: Checking Toxicity of Fungal Metabolites in the Colon.](#)

Blatzer M, Papon N, Delneste Y, Latgé JP.

Trends Endocrinol Metab. 2020 Dec 17:S1043-2760(20)30248-4.

[PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.](#)

Simon S, Voillet V, Vignard V, Wu Z, Dabrowski C, Jouand N, Beauvais T, Khammari A, Braudeau C, Josien R, Adotevi O, Laheurte C, Aubin F, Nardin C, Rulli S, Gottardo R, Ramchurren N, Cheever M, Fling SP, Church CD, Nghiem P, Dreno B, Riddell SR, Labarriere N.

J Immunother Cancer. 2020 Nov;8(2):e001631.

[Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study.](#)

Gogas H, Dréno B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, Francesco Ferrucci P, Pigozzo J, Rutkowski P, Mackiewicz J, Rooney I, Voulgari A, Troutman S, Pitcher B, Guo Y, Yan Y, Castro M, Mulla S, Flaherty K, Arance A.

Ann Oncol. 2020 Dec 10:S0923-7534(20)43203-X.

[Narrow resection margins are not associated with mortality or recurrence in patients with Merkel cell carcinoma: a retrospective study.](#)

Jaouen F, Kervarrec T, Caille A, Le Corre Y, Dreno B, Esteve E, Wierzbicka-Hainaut E, Maillard H, Dinulescu M, Blom A, Saïag P, Samimi M.

J Am Acad Dermatol. 2020 Nov 27:S0190-9622(20)33079-6.

[Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer \(CUTACETUX\).](#)

Tougeron D, Emambux S, Favot L, Lecomte T, Wierzbicka-Hainaut E, Samimi M, Frouin E, Azzopardi N, Chevrier J, Serres L, Godet J, Levillain P, Paintaud G, Ferru A, Rouleau L, Delwail A, Silvain C, Tasu JP, Morel F, Ragot S, Lecron JC.

Oncoimmunology. 2020 Nov 29;9(1):1848058.

[Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.](#)

Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Du FL, Dupré PF, Bachelot T, Gabelle P, Chauvet MP, Coeffic D, Barbe C, Prevost JB, Paintaud G, Thibault G, Ferhat A, Dupin J, Berriolo-Riedinger A, Arnould L.

EClinicalMedicine. 2020 Nov 4;28:100566.

[Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort.](#)

Aparicio T, Svrcek M, Henriques J, Afchain P, Lièvre A, Tougeron D, Gagniere J, Terrebonne E, Piessen G, Legoux JL, Lecaille C, Pocard M, Gornet JM, Zaanen A, Lavau-Denes S, Lecomte T, Deutsch D, Vernerey D, Puig PL.

Int J Cancer. 2020 Nov 13.

[PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.](#)

Evrard C, Louvet C, Hajbi FE, Fiore FD, Malicot KL, Aparicio T, Bouché O, Laurent-Puig P, Bibeau F, Lecomte T, Lièvre A, Guimbaud R, Kim S, Zaanani A, Sokol H, Chibaudel B, Desrame J, Pierre S, Gonzalez D, Lepage C, Tougeron D.

Dig Liver Dis. 2020 Dec 21:S1590-8658(20)31057-4.

[Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer \(mCRC\): A Phase II Study \(FFCD 1302\).](#)

Lapeyre-Prost A, Pernot S, Sigrand J, Le Malicot K, Mary F, Aparicio T, Dahan L, Caroli-Bosc FX, Lecomte T, Doat S, Marthey L, Desrame J, Lepage C, Taieb J.

Clin Colorectal Cancer. 2020 Dec;19(4):285-290.

[Neospora caninum: a new class of biopharmaceuticals in the therapeutic arsenal against cancer.](#)

Lantier L, Poupée-Beaugé A, di Tommaso A, Ducournau C, Epardaud M, Lakhrif Z, Germon S, Debierre-Grockiego F, Mévélec MN, Battistoni A, Coënon L, Deluce-Kakwata-Nkor N, Velge-Roussel F, Beauvillain C, Baranek T, Lee GS, Kervarrec T, Touzé A, Moiré N, Dimier-Poisson I.

J Immunother Cancer. 2020 Nov;8(2):e001242.

[BerEP4 positivity in Merkel cell carcinoma: a potential diagnosis pitfall.](#)

Kervarrec T, Tallegas M, Schrama D, Houben R, Ollier J, Clémenceau B, Vié H, Touzé A, Samimi M, Guyétant S.

J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e707-e709.

[Merkel cell carcinoma of lymph nodes without a skin primary tumor: A potential metastatic neoplasia associated with a brisk immune response.](#)

Kervarrec T, Zaragoza J, Gaboriaud P, Berthon P, Fromont G, Le Corre Y, Hainaut-Wierzbicka E, Aubin F, Bens G, Michenet P, Maillard H, Houben R, Schrama D, Caille A, Touzé A, Guyétant S, Samimi M.

J Am Acad Dermatol. 2020 Dec;83(6):1789-1792.

[Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance.](#)

Gauttier V, Pengam S, Durand J, Biteau K, Mary C, Morello A, Néel M, Porto G, Teppaz G, Thepenier V, Danger R, Vince N, Wilhelm E, Girault I, Abes R, Ruiz C, Trilleaud C, Ralph K, Trombetta ES, Garcia A, Vignard V, Martinet B, Glémain A, Bruneau S, Haspot F, Dehmani S, Duplouye P, Miyasaka M, Labarrière N, Laplaud D, Le Bas-Bernardet S, Blanquart C, Catros V, Gouraud PA, Archambeaud I, Aublé H, Metairie S, Mosnier JF, Costantini D, Blancho G, Conchon S, Vanhove B, Poirier N.

J Clin Invest. 2020 Nov 2;130(11):6109-6123.

[Comparison of survival outcomes between laparoscopic and abdominal radical hysterectomy for early-stage cervical cancer: A French multicentric study.](#)

Zaccarini F, Santy A, Dabi Y, Lavoue V, Carcopino X, Bendifallah S, Benbara A, Collinet P, Canlorbe G, Raimond E, Graesslin O, Ouldamer L, Daraï E, Huchon C, Golfier F, Touboul C, Bolze PA. J

Gynecol Obstet Hum Reprod. 2020 Dec 16;50(2):102046.



[Recurrence Pattern of Cervical Cancer Based on the Platinum Sensitivity Concept: A Multi-Institutional Study from the FRANCOGYN Group.](#)

de Foucher T, Hennebert C, Dabi Y, Ouldamer L, Lavoué V, Dion L, Canlorbe G, Bolze PA, Golfier F, Akladios C, Lecointre L, Kerbage Y, Collinet P, Bricou A, Carcopino X, Huchon C, Raimond E, Graesslin O, Owen C, Touboul C, Ballester M, Darai E, Bendifallah S.  
J Clin Med. 2020 Nov 12;9(11):3646.

[Accuracy of peritoneal carcinomatosis extent diagnosis by initial FDG PET CT in epithelial ovarian cancer: A multicentre study of the FRANCOGYN research group.](#)

Delvallée J, Rossard L, Bendifallah S, Touboul C, Collinet P, Bricou A, Huchon C, Lavoue V, Body G, Ouldamer L.  
J Gynecol Obstet Hum Reprod. 2020 Nov;49(9):101867.

[Integrative molecular profiling of autoreactive CD4 T cells in autoimmune hepatitis.](#)

Renand A, Cervera-Marzal I, Gil L, Dong C, Garcia A, Kervagoret E, Aublé H, Habes S, Chevalier C, Vavasseur F, Clémenceau B, Cardon A, Judor JP, Mosnier JF, Tanné F, Laplaud DA, Brouard S, Gournay J, Milpied P, Conchon S.  
J Hepatol. 2020 Dec;73(6):1379-1390.

[\[The yellow fever vaccine as a new cancer treatment?\].](#)

Petithomme T, Grard M, Fonteneau JF, Boisgerault N.  
Med Sci (Paris). 2020 Dec;36(12):1216-1217.



**Réseau « Niches et Epigénétique des Tumeurs »**

[Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells. CGO remercié, Projet ValAnti-PD1-R \(AOE CGO 2017\)](#)

Guyon, N., Garnier, D., Briand, J., Nadaradjane, A., Bougras-Cartron, G., Raimbourg, J., Campone, M., Heymann, D., Vallette, F. M., Frenel, J. S., & Cartron, P. F.  
Cell Death Dis. 2020 Dec 11;11(12):1048.

[DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma.](#)

Alberge JB, Magrangeas F, Wagner M, Denié S, Guérin-Charbonnel C, Campion L, Attal M, Avet-Loiseau H, Carell T, Moreau P, Minvielle S, Sérandour AA  
Clin Epigenetics. 2020 Nov 2;12(1):163.

[Sarcoma treatment in the era of molecular medicine.](#)

Grünewald TG, Alonso M, Avnet S, Banito A, Burdach S, Cidre-Aranaz F, Di Pompo G, Distel M, Dorado-Garcia H, Garcia-Castro J, González-González L, Grigoriadis AE, Kasan M, Koelsche C, Krumbholz M, Lecanda F, Lemma S, Longo DL, Madrigal-Esquivel C, Morales-Molina Á, Musa J, Ohmura S, Ory B, Pereira-Silva M, Perut F, Rodriguez R, Seeling C, Al Shaaili N, Shaabani S, Shiavone K, Sinha S, Tomazou EM, Trautmann M, Vela M, Versleijen-Jonkers YM, Visgauss J, Zalacain M, Schober SJ, Lissat A, English WR, Baldini N, Heymann D.  
EMBO Mol Med. 2020 Nov 6;12(11):e111131.



[EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung Carcinomas.](#)

EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung Carcinomas.

Lachat C, Bruyère D, Etcheverry A, Aubry M, Mosser J, Warda W, Herfs M, Hendrick E, Ferrand C, Borg C, Delage-Mourroux R, Feugeas JP, Guittaut M, Hervouet E, Peixoto P.

Cancers (Basel). 2020 Dec 5;12(12):3649

[Involvement of GPx-3 in the Reciprocal Control of Redox Metabolism in the Leukemic Niche.](#)

Vignon C, Debeissat C, Bourgeais J, Gallay N, Kouzi F, Anginot A, Picou F, Guardiola P, Ducrocq E, Foucault A, Ravalet N, Le Nail LR, Domenech J, Béné MC, Le Bousse-Kerdilès MC, Gyan E, Herault O.

Int J Mol Sci. 2020 Nov 14;21(22):8584.

[Curcumin Treatment Identifies Therapeutic Targets within Biomarkers of Liver Colonization by Highly Invasive Mesothelioma Cells-Potential Links with Sarcomas.](#)

Pouliquen DL, Boissard A, Henry C, Blandin S, Richomme P, Coqueret O, Guette C.

Cancers (Basel). 2020 Nov 16;12(11):3384.

[In vivo comparison of the proangiogenic properties of chlordecone and three of its dechlorinated derivatives formed by in situ chemical reduction.](#)

Alabed Alibrahim E, Legeay S, Billat PA, Bichon E, Guiffard I, Antignac JP, Legras P, Roux J, Bristeau S, Clere N, Faure S, Mouvet C.

Environ Sci Pollut Res Int. 2020 Nov;27(33):40953-40962.

[Serine 165 phosphorylation of SHARPIN regulates the activation of NF- \$\kappa\$ B.](#)

Thys A, Trillet K, Rosińska S, Gayraud A, Douanne T, Danger Y, Renaud CCN, Antigny L, Lavigne R, Pineau C, Com E, Vérité F, Gavard J, Bidère N.

iScience. 2020 Dec 13;24(1):101939.

**Réseau « Molécules Marines, Métabolisme et Cancer »**

[Design of new disubstituted imidazo\[1,2-b\]pyridazine derivatives as selective Haspin inhibitors. Synthesis, binding mode and anticancer biological evaluation.](#)

Elie J, Feizbakhsh O, Desban N, Josselin B, Baratte B, Bescond A, Duez J, Fant X, Bach S, Marie D, Place M, Ben Salah S, Chartier A, Berteina-Raboin S, Chaikuad A, Knapp S, Carles F, Bonnet P, Buron F, Routier S, Ruchaud S.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):1840-1853.

CGO remercié

[Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.](#)

Brahmaiah D, Kanaka Durga Bhavani A, Aparna P, Sampath Kumar N, Solhi H, Le Guevel R, Baratte B, Ruchaud S, Bach S, Singh Jadav S, Raji Reddy C, Roisnel T, Mosset P, Levoine N, Grée R.

Bioorg Med Chem. 2020 Dec 31;31:115962.

CGO remercié



« Hub Oncologie 4.0 »

[Public Health Impact of Using Biosimilars, Is Automated Follow up Relevant?](#)

Perpoil A, Grimandi G, Birklé S, Simonet JF, Chiffolleau A, Bocquet F.  
Int J Environ Res Public Health. 2020 Dec 29;18(1):186.

[L'instabilité génomique, paramètre limitant l'efficacité des thérapies ciblées en oncologie](#) [Genetic instability, a factor limiting the efficiency of targeted therapies in solid oncology].

Billaud A, Chevalier LM, Campone M, Morel A, Bigot F.  
Bull Cancer. 2020 Nov;107(11):1161-1170. **CGO remercié**

[Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients.](#)

Moreau-Bachelard C, Campion L, Robert M, Kerdraon O, Renaudeau C, Aumont M, Classe JM, Campone M, Frénel JS.  
Cancers (Basel). 2020 Dec 11;12(12):3725.



**Publications inter-réseaux**

**Réseaux « Vectorisation, Imagerie, Radiothérapies » & « Cancers des Tissus Hormono-dépendants »**

[Toxicity in patients treated with permanent prostate brachytherapy using intraoperatively built custom-linked seeds versus loose seeds.](#)

Ollivier L, Lucia F, Nguyen T, Lucas C, Bourbonne V, BouSSION N, Goasduff G, Fournier G, Pradier O, Dissaux G, Valeri A, Schick U  
J Contemp Brachytherapy. 2020 Dec;12(6):547-553.

[In Vivo Albumin-Binding of a C-Functionalized Cyclam Platform for 64 Cu-PET/CT Imaging in Breast Cancer Model.](#)

Le Bihan T, Driver CHS, Ebenhan T, Le Bris N, Zeevaart JR, Tripièr R.  
ChemMedChem. 2020 Nov 15.

[GETUG-AFU 17 : étude de phase III randomisée comparant la radiothérapie adjuvante à la radiothérapie de rattrapage précoce, combinées à l'hormonothérapie courte, pour les patients présentant un cancer de la prostate traité par prostatectomie radicale.](#)

Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, Pasquier D, Abdiche S, Gilliot O, Graff-Cailleaud P, Silva M, Bergerot P, Baumann P, Belkacemi Y, Azria D, Brihou M, Soulié M, Richaud P.  
Prog Urol. 2020 Nov;30(13):733-734.



**Réseaux « Immunothérapies » & « Cancers des Tissus Hormono-dépendants »**

[Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients.](#)

Moreau-Bachelard C, Campion L, Robert M, Kerdraon O, Renaudeau C, Aumont M, Classe JM, Campone M, Frénel JS.  
Cancers (Basel). 2020 Dec 11;12(12):3725.



**Réseaux Réseau « Niches et Epigénétique des Tumeurs » & « Vectorisation, Imagerie, Radiothérapies »**

[Sonic Hedgehog Signature in Pediatric Primary Bone Tumors: Effects of the GLI Antagonist GANT61 on Ewing's Sarcoma Tumor Growth.](#)

Mullard M, Cadé M, Morice S, Dupuy M, Danieau G, Amiaud J, Renault S, Lézot F, Brion R, Thepault RA, Ory B, Lamoureux F, Corre I, Brounais-LeRoyer B, Rédini F, Verrecchia F.  
Cancers (Basel). 2020 Nov 19;12(11):3438.

[The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth.](#)

Morice S, Mullard M, Brion R, Dupuy M, Renault S, Tesfaye R, Brounais-Le Royer B, Ory B, Redini F, Verrecchia F.  
Cancers (Basel). 2020 Dec 20;12(12):3847.



**Réseaux « Molécules Marines, Métabolisme et Cancer » & « Immunothérapies »**

[Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancer.](#)

Dolly A, Lecomte T, Bouché O, Borg C, Terrebbonne E, Douillard JY, Chautard R, Raoul W, Ternant D, Leger J, Bleuzen A, Dumas JF, Servais S, Baracos VE.  
Clin Nutr. 2020 Nov;39(11):3319-3330.

